Biomedical Engineering Reference
In-Depth Information
Efron B, Feldman D (1991) Compliance as an explanatory variable in clinical trials. J Am Stat
Assoc 86:9-17
Frangakis CE, Rubin DB (1999) Addressing complications of intention-to-treat analysis in the
combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes.
Biometrika 86:365-379
Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Keith
Henry W, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC (1996) A trial comparing
nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts
from 200 to 500 per cubic millimeter. N Engl J Med 335:1081-1090
Hiatt WR (2006) Observational studies of drug safety—aprotinin and the absence of transparency.
N Engl J Med 355(21):2171-2173
King MT, Hall J, Lancsar E, Fiebig D, Hossain I, Louviere J, Reddel HK, Jenkins CR (2007)
Patient preferences for managing asthma: results from a discrete choice experiment. Health
Econ 16(7):703-717
Lamiraud K, Geoffard P (2007) Therapeutic non-adherence: a rational behavior revealing patient
preferences? Health Econ 16(11):1185-1204
Manchanda P, Xie Y, Youn N (2008) The role of targeted communication and contagion in new
product adoption. Mark Sci 27(6):950-961
Manski C (2004) Measuring expectations. Econometrica 72(5):1329-1376
Narayanan S, Manchanda P (2009) Heterogeneous learning and the targeting of marketing
communication for new products. Mark Sci 28(3):424-441
Narayanan S, Manchanda P, Chintagunta P (2005) Temporal differences in the role of marketing
communication in new product categories. J Mark Res 42(3):278-290
Okie S (2005) Safety in numbers—monitoring risk in approved drugs. N Engl J Med 352:
1173-1176
Venkataraman S, Stremersch S (2007) The debate on infl uencing doctors' decisions: are drug
characteristics the missing link? Manag Sci 53(11):1688-1701
Search WWH ::
Custom Search